Stock Worth Mentioning Today: Is BioSpecifics Technologies Corp.’s Fuel For Real? The Stock Just Increased Again

Stock Worth Mentioning Today: Is BioSpecifics Technologies Corp.'s Fuel For Real? The Stock Just Increased Again

The stock of BioSpecifics Technologies Corp. (NASDAQ:BSTC) is a huge mover today! The stock increased 5.06% or $2.4 on November 29, hitting $49.85. About 82,988 shares traded hands or 162.37% up from the average. BioSpecifics Technologies Corp. (NASDAQ:BSTC) has risen 33.14% since April 26, 2016 and is uptrending. It has outperformed by 27.88% the S&P500.
The move comes after 7 months positive chart setup for the $338.18M company. It was reported on Nov, 29 by We have $51.84 PT which if reached, will make NASDAQ:BSTC worth $13.53M more.

Analysts await BioSpecifics Technologies Corp. (NASDAQ:BSTC) to report earnings on March, 13. They expect $0.38 earnings per share, up 5.56% or $0.02 from last year’s $0.36 per share. BSTC’s profit will be $2.58M for 32.80 P/E if the $0.38 EPS becomes a reality. After $0.42 actual earnings per share reported by BioSpecifics Technologies Corp. for the previous quarter, Wall Street now forecasts -9.52% negative EPS growth.

According to Zacks Investment Research, “BIOSPECIFICS TECHNOLOGIES is engaged in the business of producing and licensing, for sale by other, a U.S. Food and Drug Administration (FDA) approved enzyme derived from collagenase, named Collagenase ABC, and researching, developing and clinically testing additional products derived therefrom for potential use as pharmaceuticals.”

Insitutional Activity: The institutional sentiment decreased to 1.42 in Q2 2016. Its down 1.01, from 2.43 in 2016Q1. The ratio is negative, as 7 funds sold all BioSpecifics Technologies Corp. shares owned while 14 reduced positions. 8 funds bought stakes while 43 increased positions. They now own 3.62 million shares or 3.75% more from 3.49 million shares in 2016Q1.
Tocqueville Asset Mgmt Lp holds 0.01% of its portfolio in BioSpecifics Technologies Corp. (NASDAQ:BSTC) for 20,000 shares. Aqr Capital Mgmt Ltd Com accumulated 39,877 shares or 0% of the stock. Geneva Advsrs Limited Liability Co reported 14,072 shares or 0.01% of all its holdings. Rhumbline Advisers last reported 5,130 shares in the company. California Employees Retirement System holds 16,771 shares or 0% of its portfolio. The Connecticut-based Matarin Capital has invested 0% in BioSpecifics Technologies Corp. (NASDAQ:BSTC). Numeric Invsts Ltd Liability holds 0.02% of its portfolio in BioSpecifics Technologies Corp. (NASDAQ:BSTC) for 58,568 shares. Rice Hall James Associate Ltd, a California-based fund reported 121,002 shares. Financial Bank Of Montreal Can last reported 3,814 shares in the company. Moreover, Cornerstone Capital Mngmt Hldg Ltd Liability Co has 0% invested in BioSpecifics Technologies Corp. (NASDAQ:BSTC) for 3,600 shares. Tiaa Cref Inv Mgmt Ltd Liability Company holds 0% or 44,949 shares in its portfolio. Pnc Fincl Ser last reported 110,992 shares in the company. Gsa Cap Prtnrs Limited Liability Partnership has invested 0.1% of its portfolio in BioSpecifics Technologies Corp. (NASDAQ:BSTC). Blackrock Institutional Co Na holds 0% or 143,214 shares in its portfolio. Mufg Americas Hldg Corporation has invested 0% of its portfolio in BioSpecifics Technologies Corp. (NASDAQ:BSTC).

Insider Transactions: Since August 23, 2016, the stock had 0 buys, and 7 selling transactions for $1.53 million net activity. Wegman Thomas sold $127,751 worth of stock. 3,100 shares were sold by Wegman Toby, worth $127,751 on Thursday, September 15.

More notable recent BioSpecifics Technologies Corp. (NASDAQ:BSTC) news were published by: which released: “BioSpecifics Technologies Corp. Reports Third Quarter 2016 Financial Results” on November 09, 2016, also with their article: “BioSpecifics Technologies Corp. Announces Positive Data from Phase 2b Study of …” published on November 17, 2016, published: “News BioSpecifics Technologies Corp.BSTC” on February 12, 2011. More interesting news about BioSpecifics Technologies Corp. (NASDAQ:BSTC) were released by: and their article: “BioSpecifics Technologies Corp. to Report Third Quarter 2016 Financial Results …” published on November 02, 2016 as well as‘s news article titled: “BioSpecifics Technologies Corp. Has A 6-Year Expiration Date” with publication date: August 03, 2016.

BSTC Company Profile

BioSpecifics Technologies Corp. (BioSpecifics), incorporated on November 1, 1990, is a biopharmaceutical company. The Firm is engaged in the development of an injectable collagenase clostridium histolyticum (CCH) for multiple indications. The Firm has a development and license agreement with Endo International plc (Endo) for injectable collagenases for marketed indications and indications in development. CCH is marketed as XIAFLEX and as XIAPEX in Europe. The Company’s injectable collagenases are marketed for indications, such as Dupuytren’s contracture and Peyronie’s disease. BioSpecifics is conducting development work with respect to human lipoma and uterine fibroids. XIAFLEX and XIAPEX are approved in the United States, the European Union, Switzerland, Canada, Australia and Japan for the treatment of Dupuytren’s contracture. Endo manages the research and development of XIAFLEX for their licensed indications, including frozen shoulder, cellulite, canine lipoma, lateral hip fat, plantar fibromatosis and uterine fibroids.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment